A phase I/IIa trial of tolerogen for the treatment of myasthenia gravis
Phase of Trial: Phase I/II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Acetylcholine receptor peptide fragments (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Therapeutic Use
- 30 Sep 2016 Planned initiation date changed from 1 Jan 2017 to 1 Jan 2018, according to Toleranzia media release.
- 12 Aug 2016 According to a Toleranzia media release, this trial is expected to initiate in 2017.
- 18 Jul 2016 New trial record